Search

Your search keyword '"Brachmann, Saskia M."' showing total 177 results
Start Over Author "Brachmann, Saskia M."
177 results on '"Brachmann, Saskia M."'

1. Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Author

Chapeau, Emilie A., Sansregret, Laurent, Galli, Giorgio G., Chène, Patrick, Wartmann, Markus, Mourikis, Thanos P., Jaaks, Patricia, Baltschukat, Sabrina, Barbosa, Ines A. M., Bauer, Daniel, Brachmann, Saskia M., Delaunay, Clara, Estadieu, Claire, Faris, Jason E., Furet, Pascal, Harlfinger, Stefanie, Hueber, Andreas, Jiménez Núñez, Eloísa, Kodack, David P., Mandon, Emeline, Martin, Typhaine, Mesrouze, Yannick, Romanet, Vincent, Scheufler, Clemens, Sellner, Holger, Stamm, Christelle, Sterker, Dario, Tordella, Luca, Hofmann, Francesco, Soldermann, Nicolas, and Schmelzle, Tobias

Published
2024
Full Text
View/download PDF

2. Author Correction: Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Author

Chapeau, Emilie A., Sansregret, Laurent, Galli, Giorgio G., Chène, Patrick, Wartmann, Markus, Mourikis, Thanos P., Jaaks, Patricia, Baltschukat, Sabrina, Barbosa, Ines A. M., Bauer, Daniel, Brachmann, Saskia M., Delaunay, Clara, Estadieu, Claire, Faris, Jason E., Furet, Pascal, Harlfinger, Stefanie, Hueber, Andreas, Jiménez Núñez, Eloísa, Kodack, David P., Mandon, Emeline, Martin, Typhaine, Mesrouze, Yannick, Romanet, Vincent, Scheufler, Clemens, Sellner, Holger, Stamm, Christelle, Sterker, Dario, Tordella, Luca, Hofmann, Francesco, Soldermann, Nicolas, and Schmelzle, Tobias

Published
2024
Full Text
View/download PDF

4. Supplementary Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Author

Prahallad, Anirudh, primary, Weiss, Andreas, primary, Voshol, Hans, primary, Kerr, Grainne, primary, Sprouffske, Kathleen, primary, Yuan, Tina, primary, Ruddy, David, primary, Meistertzheim, Morgane, primary, Kazic-Legueux, Malika, primary, Kottarathil, Tina, primary, Piquet, Michelle, primary, Cao, Yichen, primary, Martinuzzi-Duboc, Laetitia, primary, Buhles, Alexandra, primary, Adler, Flavia, primary, Mannino, Salvatore, primary, Tordella, Luca, primary, Sansregret, Laurent, primary, Maira, Sauveur-Michel, primary, Graus Porta, Diana, primary, Fedele, Carmine, primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

5. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Author

Hofmann, Irmgard, Weiss, Andreas, Elain, Gaelle, Schwaederle, Maria, Sterker, Dario, Romanet, Vincent, Schmelzle, Tobias, Lai, Albert, Brachmann, Saskia M, Bentires-Alj, Mohamed, Roberts, Thomas M, Sellers, William R, Hofmann, Francesco, and Maira, Sauveur-Michel

Subjects
Cell Line, Tumor, Animals, Humans, Mice, Mice, Nude, Pancreatic Neoplasms, Sulfonamides, Indazoles, Benzimidazoles, ras Proteins, Mitogen-Activated Protein Kinase Kinases, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins, Protein Kinase Inhibitors, Xenograft Model Antitumor Assays, Cell Proliferation, Phosphorylation, Mutation, Models, Biological, Female, Proto-Oncogene Proteins p21(ras), Proto-Oncogene Proteins c-akt, Gene Knockdown Techniques, Phosphatidylinositol 3-Kinases, HEK293 Cells, Phosphoinositide-3 Kinase Inhibitors, Cell Line, Tumor, Nude, Models, Biological, General Science & Technology
Abstract

Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting components of these pathways. To better understand the requirements for K-RAS and its downstream signaling pathways MAPK and PI3K in pancreatic tumor maintenance, we established an inducible K-RAS knock down system that allowed us to ablate K-RAS in established tumors. Knock down of K-RAS resulted in impaired tumor growth in all pancreatic xenograft models tested, demonstrating that K-RAS expression is indeed required for tumor maintenance of K-RAS mutant pancreatic tumors. We further examined signaling downstream of K-RAS, and detected a robust reduction of pERK levels upon K-RAS knock down. In contrast, no effect on pAKT levels could be observed due to almost undetectable basal expression levels. To investigate the requirement of the MAPK and the PI3K pathways on tumor maintenance, three selected pancreatic xenograft models were tested for their response to MEK or PI3K inhibition. Tumors of all three models regressed upon MEK inhibition, but showed less pronounced response to PI3K inhibition. The effect of MEK inhibition on pancreatic xenografts could be enhanced further by combined application of a PI3K inhibitor. These data provide further rationale for testing combinations of MEK and PI3K inhibitors in clinical trials comprising a patient population with pancreatic cancer harboring mutations in K-RAS.

Published
2012

6. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Author

Prahallad, Anirudh, primary, Weiss, Andreas, additional, Voshol, Hans, additional, Kerr, Grainne, additional, Sprouffske, Kathleen, additional, Yuan, Tina, additional, Ruddy, David, additional, Meistertzheim, Morgane, additional, Kazic-Legueux, Malika, additional, Kottarathil, Tina, additional, Piquet, Michelle, additional, Cao, Yichen, additional, Martinuzzi-Duboc, Laetitia, additional, Buhles, Alexandra, additional, Adler, Flavia, additional, Mannino, Salvatore, additional, Tordella, Luca, additional, Sansregret, Laurent, additional, Maira, Sauveur-Michel, additional, Graus Porta, Diana, additional, Fedele, Carmine, additional, and Brachmann, Saskia M., additional

Published
2023
Full Text
View/download PDF

8. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

Author

McDonald, E. Robert, III, de Weck, Antoine, Schlabach, Michael R., Billy, Eric, Mavrakis, Konstantinos J., Hoffman, Gregory R., Belur, Dhiren, Castelletti, Deborah, Frias, Elizabeth, Gampa, Kalyani, Golji, Javad, Kao, Iris, Li, Li, Megel, Philippe, Perkins, Thomas A., Ramadan, Nadire, Ruddy, David A., Silver, Serena J., Sovath, Sosathya, Stump, Mark, Weber, Odile, Widmer, Roland, Yu, Jianjun, Yu, Kristine, Yue, Yingzi, Abramowski, Dorothee, Ackley, Elizabeth, Barrett, Rosemary, Berger, Joel, Bernard, Julie L., Billig, Rebecca, Brachmann, Saskia M., Buxton, Frank, Caothien, Roger, Caushi, Justina X., Chung, Franklin S., Cortés-Cros, Marta, deBeaumont, Rosalie S., Delaunay, Clara, Desplat, Aurore, Duong, William, Dwoske, Donald A., Eldridge, Richard S., Farsidjani, Ali, Feng, Fei, Feng, JiaJia, Flemming, Daisy, Forrester, William, Galli, Giorgio G., Gao, Zhenhai, Gauter, François, Gibaja, Veronica, Haas, Kristy, Hattenberger, Marc, Hood, Tami, Hurov, Kristen E., Jagani, Zainab, Jenal, Mathias, Johnson, Jennifer A., Jones, Michael D., Kapoor, Avnish, Korn, Joshua, Liu, Jilin, Liu, Qiumei, Liu, Shumei, Liu, Yue, Loo, Alice T., Macchi, Kaitlin J., Martin, Typhaine, McAllister, Gregory, Meyer, Amandine, Mollé, Sandra, Pagliarini, Raymond A., Phadke, Tanushree, Repko, Brian, Schouwey, Tanja, Shanahan, Frances, Shen, Qiong, Stamm, Christelle, Stephan, Christine, Stucke, Volker M., Tiedt, Ralph, Varadarajan, Malini, Venkatesan, Kavitha, Vitari, Alberto C., Wallroth, Marco, Weiler, Jan, Zhang, Jing, Mickanin, Craig, Myer, Vic E., Porter, Jeffery A., Lai, Albert, Bitter, Hans, Lees, Emma, Keen, Nicholas, Kauffmann, Audrey, Stegmeier, Frank, Hofmann, Francesco, Schmelzle, Tobias, and Sellers, William R.

Published
2017
Full Text
View/download PDF

11. Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, primary, Barys, Louise, primary, Beyer, Kim S., primary, Bomio-Confaglia, Claudio, primary, Burks, Heather, primary, Chen, Xueying, primary, Cui, Xiaoming, primary, de Kanter, Ruben, primary, Dharmarajan, Lekshmi, primary, Fedele, Carmine, primary, Gerspacher, Marc, primary, Guthy, Daniel Alexander, primary, Head, Victoria, primary, Jaeger, Ashley, primary, Núñez, Eloísa Jiménez, primary, Kearns, Jeffrey D., primary, Leblanc, Catherine, primary, Maira, Sauveur-Michel, primary, Murphy, Jason, primary, Oakman, Helen, primary, Ostermann, Nils, primary, Ottl, Johannes, primary, Rigollier, Pascal, primary, Roman, Danielle, primary, Schnell, Christian, primary, Sedrani, Richard, primary, Shimizu, Toshio, primary, Stringer, Rowan, primary, Vaupel, Andrea, primary, Voshol, Hans, primary, Wessels, Peter, primary, Widmer, Toni, primary, Wilcken, Rainer, primary, Xu, Kun, primary, Zecri, Frederic, primary, Farago, Anna F., primary, Cotesta, Simona, primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, primary, Barys, Louise, primary, Beyer, Kim S., primary, Bomio-Confaglia, Claudio, primary, Burks, Heather, primary, Chen, Xueying, primary, Cui, Xiaoming, primary, de Kanter, Ruben, primary, Dharmarajan, Lekshmi, primary, Fedele, Carmine, primary, Gerspacher, Marc, primary, Guthy, Daniel Alexander, primary, Head, Victoria, primary, Jaeger, Ashley, primary, Núñez, Eloísa Jiménez, primary, Kearns, Jeffrey D., primary, Leblanc, Catherine, primary, Maira, Sauveur-Michel, primary, Murphy, Jason, primary, Oakman, Helen, primary, Ostermann, Nils, primary, Ottl, Johannes, primary, Rigollier, Pascal, primary, Roman, Danielle, primary, Schnell, Christian, primary, Sedrani, Richard, primary, Shimizu, Toshio, primary, Stringer, Rowan, primary, Vaupel, Andrea, primary, Voshol, Hans, primary, Wessels, Peter, primary, Widmer, Toni, primary, Wilcken, Rainer, primary, Xu, Kun, primary, Zecri, Frederic, primary, Farago, Anna F., primary, Cotesta, Simona, primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 4 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 2 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Author

Fritsch, Christine, primary, Huang, Alan, primary, Chatenay-Rivauday, Christian, primary, Schnell, Christian, primary, Reddy, Anupama, primary, Liu, Manway, primary, Kauffmann, Audrey, primary, Guthy, Daniel, primary, Erdmann, Dirk, primary, De Pover, Alain, primary, Furet, Pascal, primary, Gao, Hui, primary, Ferretti, Stephane, primary, Wang, Youzhen, primary, Trappe, Joerg, primary, Brachmann, Saskia M., primary, Maira, Sauveur-Michel, primary, Wilson, Christopher, primary, Boehm, Markus, primary, Garcia-Echeverria, Carlos, primary, Chene, Patrick, primary, Wiesmann, Marion, primary, Cozens, Robert, primary, Lehar, Joseph, primary, Schlegel, Robert, primary, Caravatti, Giorgio, primary, Hofmann, Francesco, primary, and Sellers, William R., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 3 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 3 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Author

Fritsch, Christine, primary, Huang, Alan, primary, Chatenay-Rivauday, Christian, primary, Schnell, Christian, primary, Reddy, Anupama, primary, Liu, Manway, primary, Kauffmann, Audrey, primary, Guthy, Daniel, primary, Erdmann, Dirk, primary, De Pover, Alain, primary, Furet, Pascal, primary, Gao, Hui, primary, Ferretti, Stephane, primary, Wang, Youzhen, primary, Trappe, Joerg, primary, Brachmann, Saskia M., primary, Maira, Sauveur-Michel, primary, Wilson, Christopher, primary, Boehm, Markus, primary, Garcia-Echeverria, Carlos, primary, Chene, Patrick, primary, Wiesmann, Marion, primary, Cozens, Robert, primary, Lehar, Joseph, primary, Schlegel, Robert, primary, Caravatti, Giorgio, primary, Hofmann, Francesco, primary, and Sellers, William R., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure Legends, Supplementary Table Legends, and Supplementary Tables 1 through 7 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Author

Fritsch, Christine, primary, Huang, Alan, primary, Chatenay-Rivauday, Christian, primary, Schnell, Christian, primary, Reddy, Anupama, primary, Liu, Manway, primary, Kauffmann, Audrey, primary, Guthy, Daniel, primary, Erdmann, Dirk, primary, De Pover, Alain, primary, Furet, Pascal, primary, Gao, Hui, primary, Ferretti, Stephane, primary, Wang, Youzhen, primary, Trappe, Joerg, primary, Brachmann, Saskia M., primary, Maira, Sauveur-Michel, primary, Wilson, Christopher, primary, Boehm, Markus, primary, Garcia-Echeverria, Carlos, primary, Chene, Patrick, primary, Wiesmann, Marion, primary, Cozens, Robert, primary, Lehar, Joseph, primary, Schlegel, Robert, primary, Caravatti, Giorgio, primary, Hofmann, Francesco, primary, and Sellers, William R., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 4 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Author

Fritsch, Christine, primary, Huang, Alan, primary, Chatenay-Rivauday, Christian, primary, Schnell, Christian, primary, Reddy, Anupama, primary, Liu, Manway, primary, Kauffmann, Audrey, primary, Guthy, Daniel, primary, Erdmann, Dirk, primary, De Pover, Alain, primary, Furet, Pascal, primary, Gao, Hui, primary, Ferretti, Stephane, primary, Wang, Youzhen, primary, Trappe, Joerg, primary, Brachmann, Saskia M., primary, Maira, Sauveur-Michel, primary, Wilson, Christopher, primary, Boehm, Markus, primary, Garcia-Echeverria, Carlos, primary, Chene, Patrick, primary, Wiesmann, Marion, primary, Cozens, Robert, primary, Lehar, Joseph, primary, Schlegel, Robert, primary, Caravatti, Giorgio, primary, Hofmann, Francesco, primary, and Sellers, William R., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 6 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Methods, Table 1, and Figure Legends from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 7 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

26. Data from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 1 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Author

Fritsch, Christine, primary, Huang, Alan, primary, Chatenay-Rivauday, Christian, primary, Schnell, Christian, primary, Reddy, Anupama, primary, Liu, Manway, primary, Kauffmann, Audrey, primary, Guthy, Daniel, primary, Erdmann, Dirk, primary, De Pover, Alain, primary, Furet, Pascal, primary, Gao, Hui, primary, Ferretti, Stephane, primary, Wang, Youzhen, primary, Trappe, Joerg, primary, Brachmann, Saskia M., primary, Maira, Sauveur-Michel, primary, Wilson, Christopher, primary, Boehm, Markus, primary, Garcia-Echeverria, Carlos, primary, Chene, Patrick, primary, Wiesmann, Marion, primary, Cozens, Robert, primary, Lehar, Joseph, primary, Schlegel, Robert, primary, Caravatti, Giorgio, primary, Hofmann, Francesco, primary, and Sellers, William R., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 5 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 1 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Author

Brachmann, Saskia M., primary, Kleylein-Sohn, Julia, primary, Gaulis, Swann, primary, Kauffmann, Audrey, primary, Blommers, Marcel J.J., primary, Kazic-Legueux, Malika, primary, Laborde, Laurent, primary, Hattenberger, Marc, primary, Stauffer, Fabian, primary, Vaxelaire, Juliane, primary, Romanet, Vincent, primary, Henry, Chrystèle, primary, Murakami, Masato, primary, Guthy, Daniel Alexander, primary, Sterker, Dario, primary, Bergling, Sebastian, primary, Wilson, Christopher, primary, Brümmendorf, Thomas, primary, Fritsch, Christine, primary, Garcia-Echeverria, Carlos, primary, Sellers, William R., primary, Hofmann, Francesco, primary, and Maira, Sauveur-Michel, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure Legends from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 9 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 6 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 7 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

40. Data from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 1 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 8 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Materials and Methods from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 3 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 1 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 4 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Author

Herkert, Barbara, primary, Kauffmann, Audrey, primary, Mollé, Sandra, primary, Schnell, Christian, primary, Ferrat, Thomas, primary, Voshol, Hans, primary, Juengert, Janina, primary, Erasimus, Hélène, primary, Marszalek, Grégory, primary, Kazic-Legueux, Malika, primary, Billy, Eric, primary, Ruddy, David, primary, Stump, Mark, primary, Guthy, Daniel, primary, Ristov, Mitko, primary, Calkins, Keith, primary, Maira, Sauveur-Michel, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Hall, Michael N., primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

48. JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors

Author

Lorthiois, Edwige, primary, Gerspacher, Marc, additional, Beyer, Kim S., additional, Vaupel, Andrea, additional, Leblanc, Catherine, additional, Stringer, Rowan, additional, Weiss, Andreas, additional, Wilcken, Rainer, additional, Guthy, Daniel A., additional, Lingel, Andreas, additional, Bomio-Confaglia, Claudio, additional, Machauer, Rainer, additional, Rigollier, Pascal, additional, Ottl, Johannes, additional, Arz, Dorothee, additional, Bernet, Pascal, additional, Desjonqueres, Gaëlle, additional, Dussauge, Solene, additional, Kazic-Legueux, Malika, additional, Lozac’h, Marie-Anne, additional, Mura, Christophe, additional, Sorge, Mickaël, additional, Todorov, Milen, additional, Warin, Nicolas, additional, Zink, Florence, additional, Voshol, Hans, additional, Zecri, Frederic J., additional, Sedrani, Richard C., additional, Ostermann, Nils, additional, Brachmann, Saskia M., additional, and Cotesta, Simona, additional

Published
2022
Full Text
View/download PDF

49. Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6

Author

Weiss, Andreas, primary, Voshol, Hans, additional, Porta, Diana Graus, additional, Fedele, Carmine, additional, Sterker, Dario, additional, De Kanter, Ruben, additional, Stringer, Rowan, additional, Widmer, Toni, additional, Loo, Alice, additional, Guthy, Daniel A., additional, Beyer, Kim S., additional, Ostermann, Nils, additional, LeBlanc, Catherine, additional, Gerspacher, Marc, additional, Vaupel, Andrea, additional, Sedrani, Richard, additional, Zecri, Frederic, additional, Maria, Saveur-Michel, additional, Hofmann, Francesco, additional, Hammerman, Peter, additional, Engelman, Jeff, additional, Lorthiois, Edwige, additional, Cotesta, Simona, additional, and Brachmann, Saskia M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results